{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:50:10Z","timestamp":1792461010111,"version":"4.5.0"},"reference-count":39,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2018,9,22]]},"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the impact of extra-articular spondyloarthritis (SpA) manifestations (anterior uveitis, psoriasis and inflammatory bowel disease (IBD)), and of comorbidities, on tumour necrosis factor alpha inhibitor (TNFi) drug retention in ankylosing spondylitis (AS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified all bio-na\u00efve patients with AS starting a first ever TNFi July 2006 to December 2015 from the Swedish Rheumatology Quality register and followed these from treatment start through December 2015. We determined the presence of extra-articular SpA-manifestations, comorbidities (cardiovascular disease, affective disease, diabetes, malignancies, chronic lung disease and kidney disease) and socioeconomic status before TNFi start, through linkage to five other national registers, and calculated, for each factor, crude and adjusted HRs for discontinuing the TNFi.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>2577 patients with AS (71% men) started a first TNFi during the study period. 27% had a history of anterior uveitis, 6% psoriasis and 7% IBD. Anterior uveitis was associated with a superior TNFi drug retention (HR 0.72; 0.62 to 0.83), psoriasis with an inferior (HR 1.48; 1.18 to 1.86), whereas IBD did not affect TNFi drug retention. The effect of the SpA manifestations on TNFi drug retention was of a similar magnitude to that of the comorbidities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In AS, anterior uveitis and psoriasis, but not IBD, affect TNFi drug retention. Possible explanations include differential effects of TNFi on these extra-articular SpA manifestations, or inherent differences in AS, associated with the inflammatory phenotype. Further, comorbidities and socioeconomy affect TNFi drug retention to a similar magnitude as the SpA manifestations, and should, as such, receive due attention in clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2018-000762","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:04:22Z","timestamp":1539648262000},"page":"e000762","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study"],"prefix":"10.1136","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-9348","authenticated-orcid":false,"given":"Ulf","family":"Lindstr\u00f6m","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Olofsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Wedr\u00e9n","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Qirjazo","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Clinical Epidemiology Unit, Karolinska University Hospital Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"2025090312444338000_4.2.e000762.1","first-page":"Cd005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","volume":"18","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090312444338000_4.2.e000762.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.131797"},{"key":"2025090312444338000_4.2.e000762.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20258"},{"key":"2025090312444338000_4.2.e000762.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"2025090312444338000_4.2.e000762.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"2025090312444338000_4.2.e000762.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev392"},{"key":"2025090312444338000_4.2.e000762.7","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369"},{"key":"2025090312444338000_4.2.e000762.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150389"},{"key":"2025090312444338000_4.2.e000762.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-015-0620-4","article-title":"Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab","volume":"16","author":"Lorenzin","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2025090312444338000_4.2.e000762.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206616"},{"key":"2025090312444338000_4.2.e000762.11","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/art.39691","article-title":"The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial spondyloarthritis","volume":"68","author":"Nissen","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312444338000_4.2.e000762.12","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835257c5"},{"key":"2025090312444338000_4.2.e000762.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2025090312444338000_4.2.e000762.14","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090312444338000_4.2.e000762.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016717"},{"key":"2025090312444338000_4.2.e000762.16","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"2025090312444338000_4.2.e000762.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203582"},{"key":"2025090312444338000_4.2.e000762.18","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept","volume":"32","author":"Davis","year":"2005","journal-title":"J Rheumatol"},{"key":"2025090312444338000_4.2.e000762.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket249"},{"key":"2025090312444338000_4.2.e000762.20","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2014.756"},{"key":"2025090312444338000_4.2.e000762.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"2025090312444338000_4.2.e000762.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq129"},{"key":"2025090312444338000_4.2.e000762.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"2025090312444338000_4.2.e000762.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60026-9"},{"key":"2025090312444338000_4.2.e000762.25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? a prospective nationwide population-based cohort study","volume":"19","author":"Bengtsson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090312444338000_4.2.e000762.26","doi-asserted-by":"publisher","DOI":"10.1080\/14622200701825098"},{"key":"2025090312444338000_4.2.e000762.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205133"},{"key":"2025090312444338000_4.2.e000762.28","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2014.927918"},{"key":"2025090312444338000_4.2.e000762.29","doi-asserted-by":"crossref","unstructured":"Vittinghoff Eg D , Shiboski SC , McCulloch CE . Regression methods in biostatistics. Springer, 2012.","DOI":"10.1007\/978-1-4614-1353-0"},{"key":"2025090312444338000_4.2.e000762.30","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.55"},{"key":"2025090312444338000_4.2.e000762.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.147744"},{"key":"2025090312444338000_4.2.e000762.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"2025090312444338000_4.2.e000762.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.21197"},{"key":"2025090312444338000_4.2.e000762.34","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2025090312444338000_4.2.e000762.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210931"},{"key":"2025090312444338000_4.2.e000762.36","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"2025090312444338000_4.2.e000762.37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/bjd.15023","article-title":"Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry","volume":"176","author":"Zweegers","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025090312444338000_4.2.e000762.38","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0403-2"},{"key":"2025090312444338000_4.2.e000762.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh386"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2018-000762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:44:49Z","timestamp":1756928689000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2018-000762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,10,15]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/rmdopen-2018-000762"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2018-000762","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}